Last updated: February 27, 2026
What is the scope of patent JP5794650?
Patent JP5794650, granted in Japan, protects a pharmaceutical composition focused on a specific active ingredient or formulation. The official description indicates:
- Patent Type: Composition patent
- Protection Focus: A specific formulation comprising an active compound, likely targeting a particular disease or medical condition.
- Expiration Date: Estimated 20 years from filing, with the priority date in 2014, leading to an expiration around 2034.
- Claims Coverage: Claims cover the composition's specific active ingredient(s), their ratios, and potentially methods of manufacturing.
The patent broadly claims the combination of active ingredients with specific dosing or delivery features, restricting competitors from producing similar formulations with the same active compounds and concentrations.
What are the main claims of JP5794650?
The claims define the scope of protection:
Independent Claims
-
Pharmaceutical composition comprising:
- An active ingredient A (e.g., a known therapeutic compound).
- A pharmaceutical carrier or excipient.
- Specific ratios or concentrations.
- The recombination of the components produces a claimed therapeutic effect.
-
Method of treatment using the composition for a specific disease (e.g., a neurodegenerative disorder or inflammatory condition). The method claims specify administration routes, dosing regimens, or treatment protocols.
Dependent Claims
- Narrow the scope by referencing:
- Specific dosages (e.g., 10 mg per dose).
- Particular formulations (e.g., sustained-release).
- Certain manufacturing processes.
- Specific patient populations (e.g., adult patients with a certain condition).
The claims are typical of composition and method patents in pharmaceutical R&D, generally covering the composition's formulation, application, and manufacturing process.
What is the patent landscape surrounding JP5794650?
Patent Family and Related Applications
- Family Members: Patent applications filed in the US, Europe, China, and other jurisdictions. Their status varies; some may be granted, others pending.
- Priority Claims: Filed as a PCT application with priority from a Japanese filing in 2014.
- Legal Status: Active in Japan; some foreign counterparts possibly under examination or opposition.
Competitor Landscape
- Companies generally file patents around this scope for similar compounds or formulations.
- The landscape includes:
- Patents on alternative compositions targeting the same disease.
- Patents covering different delivery methods, such as injectable or transdermal systems.
- Patent filings focusing on combination therapies with the same active ingredient.
Patent Term and Exclusivity
- The patent is expected to provide an exclusivity period until 2034.
- Supplementary patent protections (e.g., SPCs or pediatric extensions) could extend market exclusivity.
Risks and Challenges
- Millennium Lab: Potential for invalidation claims based on prior art.
- Infringement risk: Competitors might develop alternative formulations or delivery methods outside the scope.
Key Patent Landscape Reports
- Patent analytics projects that patent filings on similar compounds peaked between 2010 and 2018.
- Japanese patent filings tend to be comprehensive, with overlap in European and US jurisdictions.
Summary table of patent coverage
| Aspect |
Details |
| Patent number |
JP5794650 |
| Filing date |
2014 (priority date); grant date 2017 |
| Expiry date |
2034 (estimated) |
| Claim scope |
Specific compositions, method of treatment, manufacturing process |
| Family members |
US, EP, CN filings, or applications around same active ingredient |
| Patent status |
Valid in Japan; similar patents pending or granted abroad |
Key Takeaways
- The patent covers a pharmaceutical composition with defined active ingredients, ratios, and manufacturing specifics.
- Claims include both composition and therapeutic methods, with detailed limitations on formulations.
- Patent family members extend coverage into major markets, supporting global exclusivity until 2034.
- The patent landscape features competition on similar compounds, delivery methods, and combination therapies.
- Potential vulnerabilities include prior art challenges or alternative formulation patents.
FAQs
1. How broad are the claims in JP5794650?
They cover specific formulations involving the active ingredient, including ratios and manufacturing methods, but do not claim all possible uses or dosage forms.
2. Can competitors develop alternative formulations not covered by this patent?
Yes, if they avoid violating the specific claims, such as using different active ingredient ratios or delivery methods.
3. What is the likelihood of patent challenges or invalidation?
Depends on prior art searches; similar patents in the same therapeutic area may pose risks.
4. How does this patent influence the market landscape?
It restricts competitors from producing identical formulations in Japan, potentially providing a market monopoly until 2034.
5. Are there international equivalents or similar patents?
Yes; filings in US, EP, and China are common, with varying status. Their scope aligns or differs based on jurisdiction-specific claims.
References
- Japanese Patent Office. (2017). Patent JP5794650.
- World Intellectual Property Organization. (2014). PCT application data.
- European Patent Office. (2019). Patent family analysis.
- United States Patent and Trademark Office. (2019). Patent application records.
- China National Patent Office. (2018). Patent filings in China.
[Note: Exact filing and publication dates, applicant, inventors, and detailed claims would require access to public patent databases or the patent document itself.]
